Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(147 produtos)
- Bcr-Abl(103 produtos)
- EGFR(572 produtos)
- FAK(71 produtos)
- FLT(91 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(88 produtos)
- Src(80 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(267 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1483 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Fórmula:C27H31ClN7O3PCor e Forma:SolidPeso molecular:568.01TZEP7
CAS:<p>TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.</p>Fórmula:C27H19ClFNSCor e Forma:SolidPeso molecular:443.963VEGFR/PDGFR-IN-1
CAS:<p>VEGFR/PDGFR-IN-1 (Compound 1) is an inhibitor of VEGFR with an IC50 of 0.4 μM. It can inhibit angiogenesis in HUVEC cells and holds promise for impeding tumor growth and metastasis.</p>Fórmula:C17H21N5O3Cor e Forma:SolidPeso molecular:343.38HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Fórmula:C20H18N4O3SCor e Forma:SolidPeso molecular:394.447Protein kinase inhibitor 10
CAS:<p>Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.</p>Fórmula:C14H9FN6S2Cor e Forma:SolidPeso molecular:344.39E7090 succinate
CAS:<p>E7090 succinate inhibits FGFR1, FGFR2, and FGFR3 with IC50: 0.71, 0.50, 1.2 nM; less so FGFR4 at 120 nM.</p>Fórmula:C76H92N10O24Cor e Forma:SolidPeso molecular:1529.60Antiallergic agent-1
<p>Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.</p>Fórmula:C27H19F6N5OCor e Forma:SolidPeso molecular:543.46VEGFR-2-IN-10
<p>VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.</p>Fórmula:C20H21N3O2Cor e Forma:SolidPeso molecular:335.4MM-589
CAS:<p>MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.</p>Fórmula:C28H44N8O5Pureza:98%Cor e Forma:SolidPeso molecular:572.70Lomonitinib
CAS:<p>Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.</p>Fórmula:C27H24N4O2Cor e Forma:SolidPeso molecular:436.505EGFR-IN-146
CAS:<p>EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.</p>Fórmula:C20H16N4Cor e Forma:SolidPeso molecular:312.368MTX-216
CAS:<p>MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.</p>Fórmula:C22H14Cl2FN5O2SCor e Forma:SolidPeso molecular:502.348FLT3/ITD-IN-1
<p>FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.</p>Fórmula:C19H22N6O2Cor e Forma:SolidPeso molecular:366.42Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Fórmula:C25H24N6O3S2Pureza:98%Cor e Forma:SolidPeso molecular:520.63(-)-Cevimeline hydrochloride hemihydrate
<p>(-)-Cevimeline HCl hemihydrate, a muscarinic agonist, treats Sjogren's xerostomia. Quick absorption, species-dependent metabolism.</p>Fórmula:C10H19ClNO1·5SPureza:98%Cor e Forma:SolidPeso molecular:244.78EGFR-IN-38
CAS:<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Fórmula:C25H24ClN7O2Cor e Forma:SolidPeso molecular:489.96Flonoltinib sulfate
CAS:<p>Flonoltinib maleate is an orally active dual inhibitor of JAK2/FLT3, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. It exhibits anticancer properties.</p>Fórmula:C25H36FN7O5SCor e Forma:SolidPeso molecular:565.661JBJ-02-112-05
CAS:<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Fórmula:C27H20N4O2SPureza:98%Cor e Forma:SolidPeso molecular:464.54Ki11502
CAS:Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.Fórmula:C26H23N3O4SPeso molecular:473.54Lazertinib mesylate
CAS:<p>Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.</p>Fórmula:C31H38N8O6SPeso molecular:650.75
